Article Details

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Retrieved on: 2021-05-06 10:06:15

Tags for this article:

Click the tags to see associated articles and topics

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody. View article details on hiswai:

Excerpt

Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral ...

Article found on: www.pmlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up